Advancing next-generation immunotherapies, targeted biologics, and adaptive immune modulation. Our pipeline spans autoimmune disorders, oncology, infectious diseases, and rare immunological conditions.
Targeting unmet medical needs through precision immunomodulation and adaptive immune reprogramming.
Next-generation biologics and oral small molecules targeting cytokine dysregulation, complement pathways, and immune checkpoint overactivation.
Bispecific antibodies, CAR-T enhancers, neoantigen vaccines, and combinatorial checkpoint inhibitors for solid and hematologic malignancies.
STING agonists, TLR modulators, and broadly neutralizing antibody platforms for viral, bacterial, and fungal pathogen resilience.
Gene editing vectors, enzyme replacement therapies, and targeted immune reconstitution for SCID, IPEX, and complement deficiencies.
Co-development and licensing agreements expanding our immunology discovery engine.